P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation.
Annamaria Gulla,Eugenio Morelli,Mehmet Kemal Samur,Cirino Botta,Teru Hideshima,Giada Bianchi,Mariateresa Fulciniti,Stefano Malvestiti,Rao Prabhala,Rao Prabhala,Srikanth Talluri,Srikanth Talluri,Kenneth Wen,Yu-Tzu Tai,Paul G. Richardson,Dharminder Chauhan,Tomasz Sewastianik,Ruben D. Carrasco,Ruben D. Carrasco,Nikhil C. Munshi,Nikhil C. Munshi,Kenneth C. Anderson +21 more
TL;DR: It is shown that bortezomib triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multipleMyeloma-specific immunity.
Journal ArticleDOI
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
David S. Siegel,Paul G. Richardson,Meletios A. Dimopoulos,Philippe Moreau,Constantine S. Mitsiades,Donna M. Weber,Jennifer Houp,Christine K. Gause,Scott Vuocolo,Joseph E. Eid,Thorsten Graef,KC Anderson +11 more
TL;DR: Vorinostat in combination with lenalidomide and dexamethasone proved tolerable with appropriate supportive care, with encouraging activity observed.
Journal ArticleDOI
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia
Irene M. Ghobrial,Federico Campigotto,Timothy J. Murphy,Erica N Boswell,Ranjit Banwait,Feda Azab,Stacey Chuma,Janet Kunsman,Amanda Donovan,Farzana Masood,Diane Warren,Scott J. Rodig,Kenneth C. Anderson,Paul G. Richardson,Edie Weller,Jeffrey Matous +15 more
TL;DR: In this article, the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM) were evaluated.
Journal ArticleDOI
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji Kumar,Philippe Moreau,Parameswaran Hari,Maria-Victoria Mateos,Heinz Ludwig,Chaim Shustik,Tamás Masszi,Andrew Spencer,Roman Hájek,Kenneth Romeril,Irit Avivi,Anna M. Liberati,Monique C. Minnema,Hermann Einsele,Sagar Lonial,Deborah Berg,Jianchang Lin,Neeraj Gupta,Dixie Lee Esseltine,Paul G. Richardson +19 more
TL;DR: IRd resulted in a significant improvement in progression‐free survival versus placebo‐Rd and no cumulative toxicities were observed, indicating the potential feasibility of long‐term IRd treatment.
Journal ArticleDOI
Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators.
Chuangxing Guo,Angelica Linton,Mehran Jalaie,Kephart Susan Elizabeth,Martha A. Ornelas,Pairish Mason Alan,Samantha Elizabeth Greasley,Paul G. Richardson,Karen A. Maegley,Michael J. Hickey,John Li,Xin Wu,Xiaodong Ji,Zhi Xie +13 more
TL;DR: The discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as potent and selective PKM2 activators which were found to have a novel binding mode is described.